-
Mashup Score: 0The Fresh Assault on Insurance Coverage Mandates | NEJM - 2 year(s) ago
Perspective from The New England Journal of Medicine — The Fresh Assault on Insurance Coverage Mandates
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective - 2 year(s) ago
Although previous paradigms of systemic therapy treated the immune system as expected collateral damage, immune cells, either manipulated or engineered, now have a central role in current strategies for advanced hematologic malignancies. Nowhere is this more apparent than in the treatment modalities of hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T cell therapy.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
In the spring of 2022, a man with a persistent cough sought care at an emergency department and was ultimately diagnosed with metastatic testicular cancer. He is presumably undergoing treatment though we do not know if that is true. We say presumably because we do not personally know this patient. We only know of him because we saw his chest X-ray on social media in a post that challenged the…
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1We are hiring again! :: fraintlab - 2 year(s) ago
The Fraint Lab is hiring again!
Source: fraintlabCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Informing the Debate about Telemedicine Reimbursement — What Do We Need to Know? | NEJM - 3 year(s) ago
Perspective from The New England Journal of Medicine — Informing the Debate about Telemedicine Reimbursement — What Do We Need to Know?
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0How scientists can inform policy decisions - 3 year(s) ago
You might know what policymakers should know. That doesn’t mean you know how to help them to use that information.
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Ellen's Light The Night Fundraiser - 3 year(s) ago
Light The Night At The Leukemia & Lymphoma Society’s Light The Night we gather as a community to celebrate, honor, and remember those touched by blood cancers. Friends, families, schools, corporate teams, and sponsors join together to bring light to the darkness of cancer. The funds raised by this c
Source: pages.lls.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Public Carry versus Public Health — The Harms to Come from the Supreme Court’s Decision in Bruen | NEJM - 3 year(s) ago
Perspective from The New England Journal of Medicine — Public Carry versus Public Health — The Harms to Come from the Supreme Court’s Decision in Bruen
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Professionals as Targets in the Culture Wars | NEJM - 3 year(s) ago
Perspective from The New England Journal of Medicine — Professionals as Targets in the Culture Wars
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Pediatric and adolescent and young adult (AYA) patients who receive many blood product transfusions, such as individuals with sickle cell disease (SCD), severe aplastic anemia (SAA) or indolent hematologic malignancies, are at high risk for developing donor-specific antibodies (DSA). DSAs with mean …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
https://t.co/vXbqtDB6ho